X0508 4 2026-02-27 true 0001599901 Avidity Biosciences, Inc. RNAM 0002022163 Skerjanec Simona C/O AVIDITY BIOSCIENCES, INC. 3020 CALLAN RD. SAN DIEGO CA 92121 true false false false false Common Stock 2026-02-27 4 D false 6692 D 0 D Stock Option (Right to Buy) 33.62 2026-02-27 4 D false 10034 D 2035-06-09 Common Stock 10034 0 D Stock Option (Right to Buy) 28.91 2026-02-27 4 D false 42308 D 2034-05-13 Common Stock 42308 0 D The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. /s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact 2026-02-27